首页> 外文期刊>Progress in Neuro-Psychopharmacology & Biological Psychiatry: An International Research, Review and News Journal >Changes in plasma Brain-derived neurotrophic factor (BDNF) levels induced by methylphenidate in children with Attention deficit-hyperactivity disorder (ADHD)
【24h】

Changes in plasma Brain-derived neurotrophic factor (BDNF) levels induced by methylphenidate in children with Attention deficit-hyperactivity disorder (ADHD)

机译:哌醋甲酯引起的儿童注意力缺陷多动障碍(ADHD)血浆脑源性神经营养因子(BDNF)水平的变化

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives: It has been suggested that BDNF may play a role in the pathogenesis of ADHD. Our aim is to determine whether methylphenidate can induce changes in plasma BDNF levels of children with ADHD. Methods: We assessed levels of plasma BDNF in 28 ADHD patients (age range. =3.5-10. years) before and after 6. weeks treatment with effective dosages of methylphenidate. Then we evaluated the correlation of levels of plasma BDNF with clinical variables, especially ADHD Conner's parents rating scale. Results: According to the paired sample T-test, the mean plasma BDNF level in the baseline was 193.06. pg/ml, whereas 271.06. pg/ml in the end point, thus showing significantly higher mean plasma BDNF levels in the post-treatment situation than in the pretreatment (t=-3.393, df. =27, p=0.002). Pearson's correlation test revealed that there was also significant negative correlation between levels of BDNF in the plasma of ADHD patients before treatment and improvement in hyperactivity symptoms with treatment (Pearson's correlation=-0.395, p=0.037). Conclusion: The mean plasma BDNF levels increased after 6. weeks of treatment with methylphenidate. Also, we found an improvement in hyperactivity symptoms with decreasing baseline plasma BDNF levels. We recommend that more studies should be conducted in order to assess the possible roles of plasma BDNF levels in treatment response prediction and prognosis.
机译:目的:已经提出BDNF可能在ADHD的发病机制中起作用。我们的目的是确定哌醋甲酯是否可引起ADHD儿童血浆BDNF水平的变化。方法:我们评估了有效剂量哌醋甲酯治疗6周前后28例ADHD患者(年龄范围= 3.5-10。岁)血浆BDNF的水平。然后,我们评估了血浆BDNF水平与临床变量之间的相关性,尤其是ADHD Conner父母的父母评定量表。结果:根据配对的T检验,基线血浆平均BDNF水平为193.06。 pg / ml,而271.06。终点为pg / ml,因此在治疗后的情况下平均血浆BDNF水平明显高于治疗前的水平(t = -3.393,df。= 27,p = 0.002)。皮尔森相关性测试显示,治疗前多动症患者血浆中BDNF水平与治疗后多动症状改善之间也存在显着负相关(皮尔森相关性= -0.395,p = 0.037)。结论:哌醋甲酯治疗6周后,平均血浆BDNF水平升高。此外,我们发现多动症症状随着基线血浆BDNF水平的降低而改善。我们建议应该进行更多的研究,以评估血浆BDNF水平在治疗反应预测和预后中的可能作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号